UNCY Unicycive Therapeutics Inc

Price (delayed)

$4.81

Market cap

$133.98M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.75

Enterprise value

$90.47M

?
Relative Growth: Rel. Growth: 20
Relative Strength: Rel. Strength: 19
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 4
Highlights
UNCY's quick ratio has soared by 99% year-on-year and by 59% since the previous quarter
The company's EPS has surged by 51% YoY and by 21% QoQ
UNCY's debt has surged by 64% year-on-year but it is down by 18% since the previous quarter
UNCY's net income is down by 12% year-on-year but it is up by 12% since the previous quarter

Key stats

What are the main financial stats of UNCY

UNCY stock price

How has the Unicycive Therapeutics stock price performed over time
Intraday
-3.02%
1 week
0.63%
1 month
-14.56%
1 year
20.85%
YTD
-16.64%
QTD
2.56%

Financial performance

How have Unicycive Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$33.14M
Net income
-$35.22M
Gross margin
N/A
Net margin
N/A
UNCY's net income is down by 12% year-on-year but it is up by 12% since the previous quarter
The company's operating income fell by 11% QoQ and by 9% YoY

Price vs fundamentals

How does UNCY's price correlate with its fundamentals

Growth

What is Unicycive Therapeutics's growth rate over time

Valuation

What is Unicycive Therapeutics stock price valuation
P/E
N/A
P/B
2.41
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has surged by 51% YoY and by 21% QoQ
The equity has increased by 41% since the previous quarter
The P/B is 22% lower than the last 4 quarters average of 3.2

Efficiency

How efficient is Unicycive Therapeutics business performance
Unicycive Therapeutics's ROE has soared by 56% YoY and by 32% from the previous quarter
UNCY's ROA is up by 39% YoY and by 27% QoQ

Dividends

What is UNCY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for UNCY.

Financial health

How did Unicycive Therapeutics financials performed over time
Unicycive Therapeutics's total assets has soared by 140% YoY and by 12% from the previous quarter
UNCY's quick ratio has soared by 99% year-on-year and by 59% since the previous quarter
UNCY's debt is 99% smaller than its equity
UNCY's debt has surged by 64% year-on-year but it is down by 18% since the previous quarter
Unicycive Therapeutics's debt to equity has shrunk by 50% QoQ and by 50% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.